HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical aspects and prognosis of ependymoma in infants and children. A single institution experience.

Abstract
Thirty-two patients (22 boys and 10 girls) with a histologically confirmed diagnosis of ependymoma were treated between 1972 and 1999. A total macroscopic resection was achieved in 16 of these patients, whereas 15 resections were classified by the surgeon as subtotal. In 1 patient a ventriculostomy was created as part of a palliative strategy. All children over 3 years old were treated with postoperative radiotherapy. Chemotherapy consisted of procarbazine, ifosfamide, etoposide, methotrexate, cisplatin and cytosine arabinoside. There was 1 perioperative death. Twenty children developed a relapse of disease within 2 months to 13 years and 1 month after the initial therapy. A maximal number of five recurrences were seen in 1 patient. The value of adjuvant chemotherapy on the prognosis of children with ependymoma seems to be limited. With regard to the poor outcome, the advisability of further treatment after multiple recurrences is debatable.
AuthorsT Humpl, H Neuser, K Brühl, U Bartels, M Schwarz, P Gutjahr
JournalChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (Childs Nerv Syst) Vol. 17 Issue 4-5 Pg. 246-51 (Apr 2001) ISSN: 0256-7040 [Print] Germany
PMID11398944 (Publication Type: Journal Article)
Topics
  • Adolescent
  • Brain (pathology)
  • Brain Neoplasms (diagnosis, pathology, therapy)
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Ependymoma (diagnosis, pathology, therapy)
  • Female
  • Humans
  • Infant
  • Male
  • Neoplasm Recurrence, Local (diagnosis, pathology, therapy)
  • Prognosis
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: